What US market access professionals need to know about pre-approval information exchange

Written by Nicole Lodowski

As payers’ evidence needs continue to evolve and formulary and budgetary decision-making becomes more complex, manufacturers have a prime opportunity to create added value by engaging with payer customers earlier and more often through pre-approval information exchange (PIE) programs. 

This free article discusses: 

  • why, historically, manufacturers have been limited in what information they were permitted to share with payers and similar entities prior to FDA approval of a drug

  • how legislation and FDA guidance has now created useful communication pathways and safe harbor for manufacturers to share much-needed pre-approval product information with payers

  • the opportunities for payers to gain valuable insights about new products and therapy areas well in advance of FDA approval and make earlier and more informed coverage and reimbursement decisions. 

FREE Whitepaper

What you need to know about pre-approval information exchange: lessons learned

Free download

We respect your privacy. Cookie policy.

Latest insights

Understanding the concept of early scientific advice ...

Black History Month 2022: Our Diversity, Equity, and ...

How a new technology add-on payment (NTAP) ...